MSLN and pancreatic ductal adenocarcinoma: (b) Introducing CAR-T cells targeting MSLN in co-treatment with proton radiation therapy: The co-expression of MSLN in pancreatic ductal adenocarcinoma (PDAC) can promote tumor development, metastasis and worse patient outcomes.